NCT00048360已完成3 期
An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 162
- 试验地点
- 22
- 主要终点
- ADHD Rating Scale
研究概览
简要总结
This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be diagnosed with ADHD.
排除标准
- •Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia.
- •Patient has a current diagnosis of Major Depressive Disorder (MDD).
- •Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months.
- •Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders.
- •Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.
结局指标
主要结局
ADHD Rating Scale
次要结局
- Clinical Global Impressions -Severity and Improvement.
- Quality of Life Enjoyment and Satisfaction Questionnaire.
研究者
研究点 (22)
Loading locations...
相似试验
招募中
3 期
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar DepressionDepression, BipolarNCT03423680Korea Otsuka Pharmaceutical Co., Ltd.390
已完成
3 期
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive DisorderMajor Depressive DisorderNCT01355081Takeda366
已完成
4 期
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)HypertensionNCT01415531Forest Laboratories641
已完成
3 期
Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)Major Depressive DisorderNCT00683592Forest Laboratories481
已完成
3 期
A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)Anxiety DisordersNCT00248183Epix Pharmaceuticals, Inc.310